Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Failure to induce remission at 10 weeks · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.94 [0.89, 0.98]
3 studies · 1132 participants
Moderate

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Remission · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 4 weeks compared with placebo (high certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.91 [0.86, 0.96]
3 studies · 1611 participants
High